ABSTRACT
Voluntary participation of the public in disease surveillance can be encouraged by deploying user-friendly sample collection processes that can minimise the discomfort to the participants. This study evaluated the suitability of saline gargle-based sample collection for genomic surveillance of SARS-CoV-2, which included 589 SARS-CoV-2 positive samples collected from Nagpur city in central India from March to December 2021. The SARS-CoV-2 positive samples were subjected to whole genome sequencing (WGS) using the oxford nanopore technologies next-generation sequencing platform. Out of 589 samples, 500 samples qualified for the WGS, and the results revealed eight different clades of SARS-CoV-2 encompassing 37 different Pango-lineage types. The mutation mapping analysis of the variants identified in this study showed six mutations of interest and one mutation of concern E484K in the spike glycoprotein region. Our findings indicate that non-invasive gargle-based genomic surveillance is scalable and does not need significant changes to the existing workflow post-sample collection.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported and funded by CSIR-NEERI, Nagpur.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Institutional Ethics Committee (IEC) of the Council of Scientific and Industrial Research-National Environmental Engineering Research Institute (CSIR-NEERI), Nagpur, India, approved the research.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
The title has been revised. Also, a section on mutational mapping of the SARS-CoV-2 variants identified in this study has been added. Accordingly, Figure 4 and Figure 5 have been added to the manuscript.
Data Availability
All data produced in the present study are available upon reasonable request to the authors
